Line 10: |
Line 10: |
| }} | | }} |
| | | |
− | ==Structure and Function of MHC Class I== | + | =Classes= |
| | | |
| + | ==MHC I== |
| ===Structure=== | | ===Structure=== |
− | | + | * MHC class I is expressed on virtually all nucleated cells |
− | * MHC class I is expressed on virtually all nucleated cells. | + | * MHC class I consists of a membrane-associated heavy chain bound non-covalently with a secreted light chain |
− | * MHC class I consists of a membrane-associated heavy chain bound non-covalently with a secreted light chain. | |
| ** Heavy chain: | | ** Heavy chain: |
− | *** Made up of three distinct extracellular protein domains. | + | *** Made up of three distinct extracellular protein domains |
− | **** α1, α2 and α3. | + | **** α1, α2 and α3 |
− | *** The C- terminus is cytoplasmic. | + | *** The C- terminus is cytoplasmic |
| ** Light chain: | | ** Light chain: |
− | *** Known as β2-microglobulin. | + | *** Known as β2-microglobulin |
− | *** Similar in structure to one of the heavy chain domains. | + | *** Similar in structure to one of the heavy chain domains |
− | *** Not membrane associated. | + | *** Not membrane associated |
− | **** But binds to the α3-domain of the heavy chain. | + | **** But binds to the α3-domain of the heavy chain |
− | * The MHC class I domains are structurally and genetically related to immunoglobulin and TcR domains. | + | * The MHC class I domains are structurally and genetically related to immunoglobulin and TcR domains |
− | ** The outer domains (α1 and α2) are like the variable domains. | + | ** The outer domains (α1 and α2) are like the variable domains |
− | ** The α3 domain and β2m are like thrconstant domains. | + | ** The α3 domain and β2m are like thrconstant domains |
− | * MHC class I molecules are folded to form specific 3-dimensional structures. | + | * MHC class I molecules are folded to form specific 3-dimensional structures |
− | ** The α1 and α2 domains are folded to produce an antigen-binding groove. | + | ** The α1 and α2 domains are folded to produce an antigen-binding groove |
− | *** This groove can bind molecules of a limited size only. | + | *** This groove can bind molecules of a limited size only (8-10 amino acids) |
− | **** 8-10 amino acids.
| + | **** This limits the size of epitope seen by the T-cell receptors |
− | **** This limits the size of epitope seen by the T-cell receptors. | |
| | | |
| ===Function=== | | ===Function=== |
| + | * MHC class I molecules bind antigenic peptides derived from within the cell and present these to the T-cell receptors of '''CD8+ T-cells''' |
| + | ** E.g. virus-encoded antigen |
| + | * Endogenously produced proteins are produced in the cell cytoplasm |
| + | ** Intracellular pathogens utilise this cellular metabolic machinery for protein synthesis |
| + | ** Many of the proteins synthesised are not used and are re-utilised by the cell |
| + | *** Peptides from these proteins are transported to the Golgi apparatus by specific transporter molecules |
| + | *** These peptides then interact with newly synthesized MHC class I molecules. |
| + | * Only MHC class I that is associated with peptide will be expressed at the surface |
| + | ** The immune system is therefore able to see antigen from intracleeular pathogens |
| | | |
− | * MHC class I molecules bind antigenic peptides derived from within the cell and present these to the T-cell receptors of CD8+ T-cells.
| |
− | ** E.g. virus-encoded antigen.
| |
− | * Endogenously produced proteins are produced in the cell cytoplasm.
| |
− | ** Intracellular pathogens utilise this cellular metabolic machinery for protein synthesis.
| |
− | ** Many of the proteins synthesised are not used and are re-utilised by the cell.
| |
− | *** Peptides from these proteins are transported to the Golgi apparatus by specific transporter molecules.
| |
− | *** These peptides then interact with newly synthesized MHC class I molecules.
| |
− | * Only MHC class I that is associated with peptide will be expressed at the surface.
| |
− | ** The immune system is therefore able to see antigen from intracleeular pathogens.
| |
− |
| |
− |
| |
− | ==Structure and Function Of MHC Class II==
| |
| | | |
| + | ==MHC II== |
| ===Structure=== | | ===Structure=== |
− | | + | * MHC class II is expressed mainly on '''macrophages''', '''dendritic cells''' and '''B-lymphocytes''' |
− | * MHC class II is expressed mainly on macrophages, dendritic cells and B-lymphocytes. | + | * MHC class II consists of membrane-associated α and β chains |
− | * MHC class II consists of membrane-associated α and β chains. | + | ** Each chain is a transmembrane glycoprotein |
− | ** Each chain is a transmembrane glycoprotein. | + | ** The extracellular parts of each chain have two Ig-like domains |
− | ** The extracellular parts of each chain have two Ig-like domains. | + | *** α1 and 7alpha;2, β1 and β2 |
− | *** α1 and 7alpha;2, β1 and β2. | + | **** The outer domains (α1 and β1) are variable-like |
− | **** The outer domains (α1 and β1) are variable-like. | + | **** The inner domains (α2 and β2) are constant-like |
− | **** The inner domains (α2 and β2) are constant-like. | + | * The 3-dimensional structure of MHC class II is similar to MHC class I |
− | * The 3-dimensional structure of MHC class II is similar to MHC class I. | + | ** The outer domains of the α and β chains fold in a similar way to the α1 and α2 domains of class I |
− | ** The outer domains of the α and β chains fold in a similar way to the α1 and α2 domains of class I. | + | *** Produce the antigen-binding groove |
− | *** Produce the antigen-binding groove. | |
| | | |
| ===Function=== | | ===Function=== |
− | | + | * MHC class II molecules bind antigenic peptides and present them to TCR on CD4+ T-cells |
− | * MHC class II molecules bind antigenic peptides and present them to TcR on CD4+ T-cells. | + | * The antigen-binding groove is larger and more open than that of MHC class I |
− | * The antigen-binding groove is larger and more open than that of MHC class I. | + | ** MHC II can therefore interact with larger peptides |
− | ** MHC II can therefore interact with larger peptides. | + | * MHC class II are present on those cells that have antigen-processing ability |
− | * MHC class II are present on those cells that have antigen-processing ability. | + | ** Interact with antigenic peptides originating from an extracellular source |
− | ** Interact with antigenic peptides originating from an extracellular source. | + | * After synthesis, MHC class II molecules are transported into special endosomes |
− | * After synthesis, MHC class II molecules are transported into special endosomes. | + | ** These endosomes fuse with lysosomes that contain the digested remnants of phagocytosed microorganisms |
− | ** These endosomes fuse with lysosomes that contain the digested remnants of phagocytosed microorganisms. | + | *** The peptides from the lysosome interact with the MHC class II molecules |
− | *** The peptides from the lysosome interact with the MHC class II molecules. | + | **** The peptide-MHC class II complex gets transported to the cell surface |
− | **** The peptide-MHC class II complex gets transported to the cell surface. | |
| | | |
| ==Interaction of MHC With Antigen== | | ==Interaction of MHC With Antigen== |
| + | * The MHC molecules do not recognise specific amino acid sequences of antigens |
| + | ** Instead, they recognise particular motifs of amino acids |
| + | * The association of any MHC allele with a peptide may be determined by the presence of as few as two amino acids |
| + | ** However, these determinants must be present within a particular array |
| + | * The actual identity of the amino acids in not important for MHC binding |
| + | ** Instead, the physical and chemical characteristics of the amino acid are vital |
| + | * Interactions of individual amino acids at the head and tail of the peptide-binding groove control the binding of peptides |
| + | ** Are mainly positioned at the floor of the antigen-binding groove, or within the helices facing into the groove |
| + | ** These MHC amino acids associate with amino acids near the ends of the peptides |
| + | *** The intervening stretch of peptide folds into a helix within the groove |
| + | *** Is the target for T cell receptor recognition |
| | | |
− | * The MHC molecules do not recognise specific amino acid sequences of antigens.
| + | ===TCR-MHC Interaction=== |
− | ** Instead, they recognise particular motifs of amino acids.
| + | * Only peptide associated with self-MHC will interact with and activate T-cells |
− | * The association of any MHC allele with a peptide may be determined by the presence of as few as two amino acids.
| + | ** T-cells cannot be activated by a peptide on a foreign cell |
− | ** However, these determinants must be present within a particular array.
| + | ** T-cells will react against foreign MHC molecules |
− | * The actual identity of the amino acids in not important for MHC binding.
| + | *** This is the basis of graft rejection |
− | ** Instead, the physical and chemical characteristics of the amino acid are vital.
| |
− | * Interactions of individual amino acids at the head and tail of the peptide-binding groove control the binding of peptides.
| |
− | ** Are mainly positioned at the floor of the antigen-binding groove, or within the helices facing into the groove.
| |
− | ** These MHC amino acids associate with amino acids near the ends of the peptides.
| |
− | *** The intervening stretch of peptide folds into a helix within the groove.
| |
− | *** Is the target for T cell receptor recognition.
| |
− | | |
− | ===TcR-MHC Interaction=== | |
− | | |
− | * Only peptide associated with self-MHC will interact with and activate T-cells. | |
− | ** T-cells cannot be activated by a peptide on a foreign cell. | |
− | ** T-cells will react against foreign MHC molecules. | |
− | *** This is the basis of graft rejection. | |
| | | |
| ===The Genetics of the MHC=== | | ===The Genetics of the MHC=== |
− | | + | * Different individuals have different critical amino acids within the MHC |
− | * Different individuals have different critical amino acids within the MHC. | + | ** I.e. different amino acids that determine peptide binding |
− | ** I.e. different amino acids that determine peptide binding. | + | ** This variation is termed '''MHC polymorphism''' |
− | ** This variation is termed '''MHC polymorphism'''. | + | * There are millions of variations in antibodies and TCR |
− | * There are millions of variations in antibodies and TcR. | + | ** However, with MHC there is very limited variation between molecules |
− | ** However, with MHC there is very limited variation between molecules. | + | * MHC polymorphism has been best studied in the human |
− | * MHC polymorphism has been best studied in the human. | |
| | | |
| ===In the Human=== | | ===In the Human=== |
− |
| |
| * Humans express: | | * Humans express: |
− | ** Three types (loci) of MHC class I molecules. | + | ** Three types (loci) of MHC class I molecules |
− | *** HLA (Human Leukocyte Antigen)- A, B, and C. | + | *** HLA (Human Leukocyte Antigen)- A, B, and C |
− | ** Three loci of MHC class II molecules. | + | ** Three loci of MHC class II molecules |
− | *** HLA-DP, DQ and DR. | + | *** HLA-DP, DQ and DR |
− | * In the entire human population there are only approximately 50 different variants (alleles) at each MHC class I and class II locus. | + | * In the entire human population there are only approximately 50 different variants (alleles) at each MHC class I and class II locus |
− | ** The variation within MHC class I is entirely on the class I heavy chain. | + | ** The variation within MHC class I is entirely on the class I heavy chain |
− | *** The β2m is invariant. | + | *** The β2m is invariant |
− | ** The variation within MHC class II is mainly within the β chains. | + | ** The variation within MHC class II is mainly within the β chains |
− | * Every individual has two alleles at each MHC locus. | + | * Every individual has two alleles at each MHC locus |
− | ** One inherited from each parent. | + | ** One inherited from each parent |
− | ** Any individual will therfore express two variants at most at each locus. | + | ** Any individual will therfore express two variants at most at each locus |
| *** This gives a maximum variability for an individual of: | | *** This gives a maximum variability for an individual of: |
− | **** 6 different variants of MHC class I. | + | **** 6 different variants of MHC class I |
− | ***** 2 each of HLA- A, B and C. | + | ***** 2 each of HLA- A, B and C |
− | **** 6 different variants of MHC class II. | + | **** 6 different variants of MHC class II |
− | ***** 2 each of HLA- DP, DQ and DR. | + | ***** 2 each of HLA- DP, DQ and DR |
− | * Many animal species have fewer loci than the human. | + | * Many animal species have fewer loci than the human |
− | ** E.g. ruminants have no MHC class II DP. | + | ** E.g. ruminants have no MHC class II DP |
| | | |
| ===MHC and Disease=== | | ===MHC and Disease=== |
− | | + | * Antigen from a pathogen has to be seen by the host MHC before an efficient immune response can occur |
− | * Antigen from a pathogen has to be seen by the host MHC before an efficient immune response can occur. | + | ** There is therefore a constant evolutionary battle between the host and the pathogen |
− | ** There is therefore a constant evolutionary battle between the host and the pathogen. | + | *** There is selective pressure on the pathogen to evolve proteins that do not interact with the host MHC |
− | *** There is selective pressure on the pathogen to evolve proteins that do not interact with the host MHC. | + | *** There is selective pressure on the host to continue to recognize the pathogen |
− | *** There is selective pressure on the host to continue to recognize the pathogen. | |
| * The consequence of this parallel evolution is that host-pathogen relationships can lead to the selection of particular MHC variants, for example: | | * The consequence of this parallel evolution is that host-pathogen relationships can lead to the selection of particular MHC variants, for example: |
− | ** MHC class II alleles DR13/DR1*1301 are prevalent in Central and Western Africa . | + | ** MHC class II alleles DR13/DR1*1301 are prevalent in Central and Western Africa |
− | *** Impart resistance to malaria. | + | *** Impart resistance to malaria |
− | ** MHC-DRB1 is prevalent in Western Europe, but rare in the Inuit populations of North America. | + | ** MHC-DRB1 is prevalent in Western Europe, but rare in the Inuit populations of North America |
− | *** Associated with the clearance of hepatitis B infection in Western Europe. | + | *** Associated with the clearance of hepatitis B infection in Western Europe |
− | *** Inuits have the highest incidence of hepatitis B in the world. | + | *** Inuits have the highest incidence of hepatitis B in the world |
| ** In humans there are also strong associations between certain alleles and some autoimmune diseases, for example: | | ** In humans there are also strong associations between certain alleles and some autoimmune diseases, for example: |
− | *** Diabetes mellitus. | + | *** Diabetes mellitus |
− | *** Ankylosing spondylitis. | + | *** Ankylosing spondylitis |
− | *** Rheumatoid arthritis. | + | *** Rheumatoid arthritis |